huTFRC/huSNCA(3'UTR)/hutau Mouse
製品名
huTFRC/huSNCA(3'UTR)/hutau Mouse
製品ID
C002100
系統名
C57BL/6J;6NCya-Tfrctm2(hTFRC)Sncatm2(hSNCA)Mapttm1(hMAPT)/Cya
背景情報
C57BL/6J;6NCya
状況
このマウス系統を論文で使用する場合は、「huTFRC/huSNCA(3'UTR)/hutau Mouse（カタログ番号C002100）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子別名
TAU, MSTD, PPND, DDPAC, MAPTL, MTBT1, MTBT2, tau-40, FTDP-17, PPP1R103, Tau-PHF6, PD1, NACP, PARK1, PARK4, T9, TR, TFR, p90, CD71, TFR1, TRFR, IMD46
染色体
Chr 17, Chr 4, Chr 3
MGI ID
さらに
系統詳細
The huTFRC/huSNCA(3'UTR)/hutau mouse is a triple-gene humanized model generated by crossing the huTFRC mouse (Catalog No.: C001860), the huSNCA(2) mouse (Catalog No.: C001698), and the huTau(MAPT) mouse (Catalog No.: C001410). This model can be used for evaluating TFRC-mediated blood-brain barrier (BBB) delivery strategies, as well as for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of TFRC/SNCA/MAPT-targeted therapeutics. It provides a valuable preclinical platform for developing innovative therapies for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases.
系統作製戦略
The huTFRC/huSNCA(3'UTR)/hutau mouse is a triple-gene humanized model obtained by crossing the huTFRC mouse (Catalog No.: C001860), the huSNCA(2) mouse (Catalog No.: C001698), and the huTau(MAPT) mouse (Catalog No.: C001410).
Figure 1. Gene editing strategy of huTFRC mice. The mouse Tfrc endogenous extracellular domain was replaced with the human TFRC extracellular domain. The murine cytoplasmic and helical domains were retained.
Figure 2. Gene editing strategy of huSNCA(2) mice. The sequences from the start codon to downstream of the 3'UTR of the endogenous mouse Snca gene were replaced with the sequences from the start codon to downstream of the 3'UTR of the human SNCA gene.
Figure 3. Gene editing strategy of huTau(MAPT) mice. The sequences from the start codon to downstream of the endogenous mouse Mapt gene were replaced with the sequences from the start codon to downstream of the human MAPT gene. The humanized regions include the 3'UTR.
適用分野
Screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of TFRC/SNCA/MAPT-targeted therapeutics;
Development of therapies for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases;
Evaluation of TFRC-mediated blood-brain barrier (BBB) delivery strategies.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。